PHK
JBIO icon

Point72 Hong Kong’s Jade Biosciences JBIO Stock Holding History

Point72 Hong Kong’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8
Closed -$6K – 1883
2021
Q3 		$6K Buy
+8
New +$4.48K ﹤0.01% 1821

Other funds holding JBIO

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

Point72 Hong Kong's JBIO Position: Q4 2021 in Review

Point72 Hong Kong sold out of Jade Biosciences (JBIO) in Q4 2021, closing a stake of 8 shares — an estimated $6K sold.

Point72 Hong Kong first reported a position in JBIO in Q3 2021 and held it in 1 quarter. The position peaked at $6K in Q3 2021. 47 funds tracked by Wall St. Rank hold JBIO as of Q4 2021.

  • Point72 Hong Kong reported no remaining Jade Biosciences position as of Q4 2021 after selling out during the quarter.
  • Point72 Hong Kong sold 8 Jade Biosciences shares in Q4 2021, an estimated $6K.
  • Point72 Hong Kong first reported a position in Jade Biosciences in Q3 2021 and held it in 1 quarter.
  • Point72 Hong Kong's Jade Biosciences position peaked at $6K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2021.

Based on Point72 Hong Kong's 13F filing for Q4 2021, filed 14 Feb 2022.